{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:54:07Z","timestamp":1774976047425,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00223-020-00754-8","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:03:19Z","timestamp":1599930199000},"page":"567-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Simple-to-Use Score for Identifying Individuals at High Risk of Denosumab-Associated Hypocalcemia in Postmenopausal Osteoporosis: A Real-World Cohort Study"],"prefix":"10.1007","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7925-2515","authenticated-orcid":false,"given":"Kyoung Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8246-1956","authenticated-orcid":false,"given":"Namki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-183X","authenticated-orcid":false,"given":"Seunghyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-4199","authenticated-orcid":false,"given":"Miryung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","volume":"16","author":"MA Bolognese","year":"2013","unstructured":"Bolognese MA, Teglbj\u00e6rg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, H\u00f8iseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C (2013) Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 16:147\u2013153","journal-title":"J Clin Densitom"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/11203300-000000000-00000","volume":"28","author":"MD Moen","year":"2011","unstructured":"Moen MD, Keam SJ (2011) Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 28:63\u201382","journal-title":"Drugs Aging"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/11587570-000000000-00000","volume":"71","author":"J-Y Reginster","year":"2011","unstructured":"Reginster J-Y (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65\u201378","journal-title":"Drugs"},{"key":"754_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694\u2013701","journal-title":"J Bone Miner Res"},{"key":"754_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"754_CR7","first-page":"1243","volume":"J43","author":"N Farinola","year":"2013","unstructured":"Farinola N, Kanjanapan Y (2013) Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J43:1243\u20131246","journal-title":"Intern Med"},{"key":"754_CR8","first-page":"756","volume":"31","author":"P Ungprasert","year":"2013","unstructured":"Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF (2013) Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 31:756","journal-title":"Am J Emerg Med"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13181-016-0543-y","volume":"12","author":"LK Laskowski","year":"2016","unstructured":"Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW (2016) A RANKL wrinkle: denosumab-induced hypocalcemia. J Med Toxicol 12:305\u2013308","journal-title":"J Med Toxicol"},{"key":"754_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","volume":"31","author":"G Tsvetov","year":"2020","unstructured":"Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T (2020) Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int 31:655\u2013665","journal-title":"Osteoporos Int"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","volume":"51","author":"JJ Body","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Dami\u00e3o R et al (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51:1812\u20131821","journal-title":"Eur J Cancer"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson B, Str\u00f6m O, Eisman JA, Papaioannou A, Siris E, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967\u2013982","journal-title":"Osteoporos Int"},{"key":"754_CR13","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","volume":"36","author":"N Okada","year":"2013","unstructured":"Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 36:1622\u20131626","journal-title":"Biol Pharm Bull"},{"key":"754_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"Dave V, Chiang CY, Booth J, Mount PF (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4\u20135. Am J Nephrol 41:129\u2013137","journal-title":"Am J Nephrol"},{"key":"754_CR15","first-page":"565393","volume":"2014","author":"M Muqeet Adnan","year":"2014","unstructured":"Muqeet Adnan M, Bhutta U, Iqbal T, AbdulMujeeb S, Haragsim L, Amer S (2014) Severe hypocalcemia due to denosumab in metastatic prostate cancer. Case Rep Nephrol 2014:565393","journal-title":"Case Rep Nephrol"},{"key":"754_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/imj.13097","volume":"46","author":"J Killen","year":"2016","unstructured":"Killen J, Yong K, Luxton G, Endre Z (2016) Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease. Intern Med J 46:746\u2013747","journal-title":"Intern Med J"},{"key":"754_CR17","unstructured":"Program NCICTE (2003) Common Terminology Criteria For Adverse Events: (CTCAE): Cancer Therapy Evaluation Program."},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00198-018-4688-1","volume":"30","author":"D Miyaoka","year":"2019","unstructured":"Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S et al (2019) Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int 30:241\u2013249","journal-title":"Osteoporos Int"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.24171\/j.phrp.2018.9.5.04","volume":"9","author":"J-T Han","year":"2018","unstructured":"Han J-T, Park I-S, Kang S-B, Seo B-G (2018) Developing the high-risk drinking scorecard model in Korea. Osong Public Health Res Perspect 9:231","journal-title":"Osong Public Health Res Perspect"},{"key":"754_CR20","volume-title":"Credit Risk scorecards: developing and implementing intelligent credit scoring","author":"N Siddiqi","year":"2006","unstructured":"Siddiqi N (2006) Credit Risk scorecards: developing and implementing intelligent credit scoring. Wiley, New York"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/21556660.2012.668504","volume":"1","author":"DB Talreja","year":"2012","unstructured":"Talreja DB (2012) Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assess 1:30\u201333","journal-title":"J Drug Assess"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1185\/03007995.2013.813840","volume":"29","author":"W-X Qi","year":"2013","unstructured":"Qi W-X, Lin F, He A-N, Tang L-N, Shen Z, Yao Y (2013) Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29:1067\u20131073","journal-title":"Curr Med Res Opin"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5694\/mja13.10038","volume":"199","author":"JM McLachlan","year":"2013","unstructured":"McLachlan JM, Marx GM, Bridgman M (2013) Severe symptomatic hypocalcaemia following a single dose of denosumab. Med J Aust 199:242\u2013243","journal-title":"Med J Aust"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479","journal-title":"J Bone Miner Res"},{"key":"754_CR25","first-page":"542","volume":"34","author":"AE Sirvent","year":"2014","unstructured":"Sirvent AE, Enr\u00edquez R, S\u00e1nchez M, Gonz\u00e1lez C, Mill\u00e1n I, Amor\u00f3s F (2014) Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease? Nefrolog\u00eda (English Edition) 34:542\u2013544","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"754_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.amjms.2017.09.008","volume":"355","author":"SA Salim","year":"2018","unstructured":"Salim SA, Nair LR, Thomas L, Garla V, Palabindala V, Agarwal M, F\u00fcl\u00f6p T (2018) Denosumab-associated severe hypocalcemia in a patient with chronic kidney disease. Am J Med Sci 355:506\u2013509","journal-title":"Am J Med Sci"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1053\/j.ajkd.2013.12.018","volume":"64","author":"PD Miller","year":"2014","unstructured":"Miller PD (2014) Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64:290\u2013304","journal-title":"Am J Kidney Dis"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00774-009-0119-x","volume":"27","author":"G Liamis","year":"2009","unstructured":"Liamis G, Milionis HJ, Elisaf M (2009) A review of drug-induced hypocalcemia. J Bone Miner Metab 27:635\u2013642","journal-title":"J Bone Miner Metab"},{"key":"754_CR29","doi-asserted-by":"publisher","first-page":"17021","DOI":"10.1038\/boneres.2017.21","volume":"5","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Suzuki T, Kamimura M, Murakami K, Ikegami S, Uchiyama S, Kato H (2017) Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res 5:17021","journal-title":"Bone Res"},{"key":"754_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00198-007-0362-8","volume":"18","author":"ND Nguyen","year":"2007","unstructured":"Nguyen ND, Frost S, Center JR, Eisman JA, Nguyen T (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18:1109\u20131117","journal-title":"Osteoporos Int"},{"key":"754_CR31","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1136\/bmj.39582.589433.BE","volume":"336","author":"MS Cooper","year":"2008","unstructured":"Cooper MS, Gittoes NJ (2008) Diagnosis and management of hypocalcaemia. BMJ 336:1298\u20131302","journal-title":"BMJ"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-020-00754-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:32:21Z","timestamp":1631406741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-020-00754-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s00223-020-00754-8","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors declare there are no conflicts of interest regarding this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Severance Hospital (IRB number: 4-2020-0159).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}